News/ News/ Oncology Ambrx tries another IPO as it chases down HER2 rivals Phil Taylor Ambrx Biopharma, antibody-drug conjugate, AstraZeneca, Enhertu, financing, her2, IPO, Kadcyla, Roche 0 Comment California biotech Ambrx Biopharma is hoping to raise $126 million from a listing on the New York Stock Share X Ambrx tries another IPO as it chases down HER2 rivals https://pharmaphorum.com/news/ambrx-tries-another-ipo-as-it-chases-down-her2-rivals/